Changes in AIDS-defining illnesses in a London Clinic, 1987-1998

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 5, 1999, Pages 401-407

  Mocroft, A ^a,b   Sabin, C A ^a   Youle, M ^a   Madge, S ^a   Tyrer, M ^a   Devereux, H ^b   Deayton, J ^a   Dykhoff, A ^a   Lipman, M C I ^a   Phillips, A N ^a   Johnson, M A ^a  

^a Dept of Prim Care and Pop Sci ^*  (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AIDS; Defining illness

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DEMENTIA; DISEASE ASSOCIATION; HUMAN; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; RETROVIRUS;

EID: 0032838902     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199908150-00007     Document Type: Article

References (39)

1. Mocroft A, Youle M, Phillips AN, et al. The incidence of AIDS defining illnesses in 4883 patients with human immunodeficiency virus infection. Arch Intern Med 1998;158:491-7.
2. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633-42.
3. Hanson DL, Chu S, Farizio KM, Ward JW and the Adult and Adolescent Spectrum of HIV Disease Project Group. Distribution of CD4-lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Intern Med 1995;155:1537-42.
4. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
5. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-I infection to AIDS. Lancet 1991;338:265-9.
6. Luo K, Law M, Kaldor JM, McDonald AM, Cooper DA. The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995;9:57-63.
7. Turner BJ, Markson LE, McKee L, Houchens R, Fanning T. The AIDS-defining diagnosis and subsequent complications: a survival based severity index. J Acquir Immune Defic Syndr 1991;4:1059-71.
8. Lundgren JD, Pedersen C, Clumeck N, et al. Survival differences in patients with AIDS, 1979-1989. BMJ 1994;308:1068-73.
9. Mocroft AJ, Lundgren JD, d'Arminio Monforte A, et al. Survival of AIDS patients according to type of AIDS-defining event. Int J Epidemiol 1997;26:400-7.
10. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-30.
11. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
12. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
13. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France 1995-1995. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:358-64.
14. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997;11:F101-5.
15. Mocroft A, Barry S, Sabin CA, et al. The changing pattern of hospital admissions among patients with HIV: Royal Free Hospital 1987-1997. AIDS (in press).
16. Egger M. Opportunistic Infections in the era of HAART [abstract 76], XII World AIDS Conference, Geneva, 1998.
17. Costagliola D. Clinical manifestations of HIV infections in the era of highly active antiretroviral treatment (HAART) in France [abstract 12345]. XII World AIDS Conference, Geneva, 1998.
18. Mocroft A, Sabin CA, Youle M, et al. Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-1997. J HIV Med (in press).
19. Update: trends in AIDS incidence United States 1996. MMWR Morb Mortal Wkly Rep 1997;46:861-7.
20. Friedman Y, Franklin C, Freels S, Weil MH. Long-term survival of patients with AIDS, Pneumocystis carinii pneumonia, and respiratory failure. JAMA 1991;266:89-92.
21. Chaisson RE, Keruly J, Richman DD, Moore RD. Pneumocystis prophylaxis and survival in Patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992;152:2009-13.
22. Bennett CL, Garfinkle JB, Greenfield S, et al. The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP. JAMA 1989;261:2975-9.
23. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6.
24. Whitmore-Overton E, Tillet HE, Evans BG, Allardice GM. Improved survival from diagnosis of AIDS in adult cases in the United Kingdom and bias due to reporting delays. AIDS 1993;7: 415-20.
25. Fischl MA, Richman D, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:185-91.
26. Miller V, Mocroft A, Reiss P, et al. Disease progression in patients with HIV-1 infection relationship with antiretroviral treatment and increasing CD4 lymphocyte counts. Ann Intern Med 1999;130: 570-7
27. + lymphocytes as prognostic markers of HIV infection. Ann Intern Med 1997;126:946-54.
28. Pitchenik AE, Fertel D, Bloch AB. Mycobacterial disease: epidemiology, diagnosis, treatment and prevention. Clin Chest Med 1988;9:425-41.
29. Mocroft A, Youle M, Morcinek J, et al. Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. BMJ 1997;314:409-13.
30. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1801-90.
31. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996;348:283-91.
32. Saravolitz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-1106.
33. Anonymous. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349: 1413-21.
34. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
35. Gullick RM, Mellors JM, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
36. Collier AC, Coombs RW, Schoenfield DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996;334:1011-17.
37. Gullick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 1998;280:35-41.
38. Del Amo J, Petruckevitch A, Phillips A, et al. Disease progression and survival in HIV-1 infected Africans in London. AIDS 1998; 12:1203-9.
39. Swaden LS, Wake A, Johnson MA. The impact on drug budgets and patient care patterns of the introduction of triple therapy [abstract 025]. Presented at the 4th Annual Meeting of the British HIV association (BHIVA), U.K., 1998.